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Abstract
Objective To evaluate the effectiveness of register based, yearly
chlamydia screening.
DesignControlled trial with randomised stepped wedge implementation
in three blocks.
Setting Three regions of the Netherlands: Amsterdam, Rotterdam, and
South Limburg.
Participants 317 304 women and men aged 16-29 years listed on
municipal registers at start of trial.
Intervention From March 2008 to February 2011, the Chlamydia
Screening Implementation programme offered yearly chlamydia screening
tests. Postal invitations asked people to use an internet site to request
a kit for self collection of samples, which would then be sent to regional
laboratories for testing. Treatment and partner notification were done
by the general practitioner or at a sexually transmitted infection clinic.
Main outcome measures Primary outcomes were the percentage of
chlamydia tests positive (positivity), percentage of invitees returning a
specimen (uptake), and estimated chlamydia prevalence. Secondary
outcomes were positivity according to sex, age, region, and
sociodemographic factors; adherence to screening invitations; and
incidence of self reported pelvic inflammatory disease.
Results The participation rate was 16.1% (43 358/269 273) after the
first invitation, 10.8% after the second, and 9.5% after the third, compared
with 13.0% (6223/48 031) in the control block invited at the end of round
two of the intervention. Chlamydia positivity in the intervention blocks at
the first invitation was the same as in the control block (4.3%) and 0.2%
lower at the third invitation (odds ratio 0.96 (95% confidence interval
0.83 to 1.10)). No substantial decreases in positivity were seen after
three screening rounds in any region or sociodemographic group. Among
the people who participated three times (2.8% of all invitees), positivity
fell from 5.9% to 2.9% (odds ratio 0.49 (0.47 to 0.50)).
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Conclusions There was no statistical evidence of an impact on
chlamydia positivity rates or estimated population prevalence from the
Chlamydia Screening Implementation programme after three years at
the participation levels obtained. The current evidence does not support
a national roll out of this register based chlamydia screening programme.
Trial registration NTR 3071 (Netherlands Trial Register, www.
trialregister.nl).
Introduction
Chlamydia screening has been promoted as a means of
controlling sexual transmission of Chlamydia trachomatis
(chlamydia),1-3 which is the most common notifiable infection
in some high income countries.1Before introducing a screening
programme there should be evidence from high quality
randomised controlled trials that the screening programme is
effective in reducing mortality or morbidity.4 The goals of
chlamydia screening are to detect and treat asymptomatic
infections, to limit ongoing transmission in the community, and
to reduce the incidence of pelvic inflammatory disease.5 Pelvic
inflammatory disease results from microorganisms, including
C trachomatis, ascending to the upper genital tract and is a
strong risk factor for tubal factor infertility and ectopic
pregnancy.6 The efficacy of a one-off offer of screening in
preventing pelvic inflammatory disease has been shown in three
randomised trials (in the US, Denmark, and UK), all of which
reported a reduction in incidence in the intervention group after
one year of follow-up.7-9 The most recent trial, with methods
with the lowest risk of bias, showed the smallest effect (risk
ratio 0.65 (95% confidence interval 0.34 to 1.22)).9
We lack evidence from randomised controlled trials that either
opportunistic or register based repeated chlamydia screening
reduces the prevalence of chlamydia in the population.10
Nevertheless, opportunistic chlamydia screening is widely
practised.11 12 The National Chlamydia Screening Programme
in England recommends chlamydia screening for sexually active
women and men under 25 years of age every year and after a
change of sexual partner.2 5 The number of chlamydia tests in
England has increased since the start of the programme in 2003
to cover 33% of all 15-24 year olds in 2010-11, when tests from
both the programme and all other sources are included.13 The
population impact of the programme is not known, however,
because population chlamydia prevalence has never been
measured as an end point.14 To evaluate the effect of screening
on chlamydia transmission, multiple screening rounds and
implementation of screening in geographically defined clusters
are needed because repeated infection after treatment is
common,15 and sexual partners need to be invited at the same
time.16 This is because screening of a population in clusters is
more likely to reduce immediate re-infection within sexual
partnerships or transmission in local sexual networks than
allocation of individuals to intervention and control groups and
helps prevent “Why me?” questions that would arise if people
in the same neighbourhoods received invitations at different
times.
The feasibility of a single round of register based chlamydia
screening has been examined in uncontrolled studies in the UK
and the Netherlands.17-19 In the Netherlands, in 2002-03 kits for
self sampling were sent to a selection of 21 000 15-29 year old
adults: 41% returned a sample, and 2.0% (95% confidence
interval 1.7% to 2.3%) were chlamydia positive.19 On the basis
of these results, the DutchMinistry of Health decided to consider
a national chlamydia screening programme if there was evidence
of feasibility, effectiveness, and cost effectiveness.3 The
objectives of this study were to investigate the effects of yearly
invitations for chlamydia screening on the percentage of positive
chlamydia test results (positivity), uptake of chlamydia
screening, and estimated chlamydia prevalence among sexually
active women and men in the Netherlands.
Methods
The intervention20 and evaluation21 of the Chlamydia Screening
Implementation project have been described in detail. Results
from the first year of screening,20-22 process evaluations,23 24 and
experiences of participants and non-responders25 have been
published. The main features of the trial are summarised here.
Study setting and participants
The study took place in three regions of the Netherlands—the
urban areas of Amsterdam and Rotterdam and a defined
suburban area of South Limburg (Parkstad). All women and
men aged 16-29 years old who were listed on the municipal
population register from March 2008 to February 2011 were
eligible to participate. Clusters were geographical and
administrative units that included about 2000 people in the target
age group in the cities and 1000 in South Limburg, resulting in
82 clusters (158 545 people) in Amsterdam, 62 clusters (119
868 people) in Rotterdam, and 46 clusters (38 891 people) in
South Limburg.
Interventions and blinding
The intervention was a register based programme with
personalised yearly invitations to be screened forC trachomatis
infection sent to the target population. The letter included the
address of the programmewebsite (www.chlamydiatest.nl) and
a secure login code through which eligible participants could
request a kit for self sampling (urine for men, vaginal swab or
urine for women).20 Samples could be posted in prepaid secure
packaging for testing by means of nucleic acid amplification
tests. A single reminder letter was sent to anyone who did not
access the website within four weeks, and email reminders were
sent to individuals who requested a kit but did not return a
specimen within two weeks.24 Test results, with a referral letter
for those with positive results, were provided online, with an
email or text message reminder after 14 and 28 days and a letter
by post after six weeks for those who did not access it.
Treatment and partner notification were provided by the person’s
general practitioner or at a local sexually transmitted infections
clinic. People with a positive test were sent a retest kit six
months after treatment. In Amsterdam and Rotterdam, all people
who reported that they ever had sex were asked to request a test
kit. In South Limburg, chlamydia prevalence was expected to
be lower than in the cities, and test kits were only sent to people
completing a risk assessment form that had been developed
previously.26 A risk score of ≥6 with the form was compatible
with a positivity of 4-5% and excluded 20-30% of potential
participants.27 Participants provided informed consent online.
The control condition was usual care. Testing for chlamydia is
available from general practitioners and at sexually transmitted
infections clinics. There was no specific promotion of chlamydia
testing during the trial period. Investigators, participants, and
laboratory staff could not be blinded to allocation to intervention
or control care.
Comparison groups and randomised stepped
wedge implementation
The intervention was implemented bymeans of a stepped wedge
design, with sequential roll out to clusters in a randomly
determined order over time so that, by the end of the three year
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study period, each cluster had been invited at least once.21 The
original study design encompassed 26 months of screening. To
allow the evaluation of up to three screening rounds, clusters
in the three regions were divided into three groups, called blocks
A, B, and C (blocks were not geographically contiguous). Block
A was smaller in the cities (one sixth of the population; invited
three times); block B included two thirds of the population
(invited twice); and block C (one sixth of the population, invited
once after the second invitation was sent to blocks A and B)
was the control group. The programme was subsequently
prolonged by six months, allowing a third invitation in block
B. In the smaller rural area, clusters were divided into three
blocks of the same size to maximise statistical power.
Allocation of clusters—Clusters were allocated by twomembers
of the evaluation team (ELMOdC and IVFvdB) who were
blinded to the identity of clusters. Before allocation, clusters
were stratified into three levels of community risk for chlamydia
infection (high, medium, or low) based on demographic factors
associated with chlamydia test positivity in the Netherlands
(that is, proportions of 16-29 year olds, of Surinamese and
Antillean residents, and of residents in the lowest income
category; also level of urbanisation in the South Limburg
region).19 For each region, cluster names were replaced by
numbers and listed by cluster size and risk level. The
investigators allocated de-identified clusters so that the required
block sizes for A, B, and C were achieved and similar
proportions of high, medium, and low risk target population per
block were obtained. The results of the allocation and
geographical distribution of clusters have been reported
elsewhere.21
Randomised stepped wedge roll out—The order of invitation of
clusters was randomised by assigning computer generated
random numbers to clusters and then sorting clusters within one
block using these numbers (using Microsoft Excel 2002). The
order of clusters was then used to generate daily lists of 600
invitees from each of the regional municipal registers and
forward these to the logistics company for mailing.
Sample size calculation
The sample size and numbers of clusters were determined by
the actual size of the target population (16-29 year old women
and men) in the three regions. The size of the control group
blocks (one sixth of the population in the cities and one third
in South Limburg) was determined to obtainmaximum statistical
power. Power calculations were based on the pilot feasibility
study, which found participation of 30% and 3% of chlamydia
tests positive in urban areas.19
Monte Carlo simulations of chlamydia positivity before and
after screening in hypothetical clusters (assuming that positivity
ranged from 0 to 10%with an average of 4%, 5%, or 6% before
screening) were run to determine the minimum detectable
decline with given population numbers for the three regions and
for each block.21 The trial had sufficient power (80%, α 0.05)
to detect an absolute overall reduction of 1% in prevalence after
one or two screening rounds if participation rates were at least
10% in Amsterdam and Rotterdam and 25% in South Limburg
with the baseline assumptions. After the first screening round,
revised simulations resulted in a minimal detectable decline of
0.5% in positivity rate for Amsterdam, 0.8% in Rotterdam, and
1.2% in Limburg, whereas, for comparisons with the control
block, the declines would need to exceed 1.2% to 1.5% if
participation rates in the second and third rounds were similar.
Outcomes
The effectiveness of chlamydia screening was planned to be
based on three primary outcomes; chlamydia test positivity,
percentage participating, and estimated chlamydia prevalence
in all regions. The main aim of the intervention was to reduce
chlamydia prevalence in intervention areas, but prevalence could
not be measured directly because, at the expected levels of
screening uptake, the percentage of positive chlamydia tests is
not a reliable estimate of population prevalence. The power
calculation was therefore based on chlamydia positivity, and
this is the primary outcome reported. Secondary outcomes were
chlamydia test positivity and test uptake by sex, age, ethnic
group, and region; estimated chlamydia prevalence; and
incidence of self reported pelvic inflammatory disease.
Statistical analysis
We calculated absolute differences and odds ratios comparing
chlamydia test positivity in intervention blocks and control
blocks and, within intervention blocks, changes between the
first and third rounds. Cluster effects for participation and
positivity rates were calculated for round one usingmultivariable
logistic regression with the variable “cluster” added as a second
level. Clustering had a modest impact on participation rates
(adjusted median odds ratio for cluster 1.14 (95% confidence
interval 1.11 to 1.16), P<0.001) and no impact on positivity
(median odds ratio 1.03 (1.0 to 1.14)) so we report participation
rates adjusted for clustering and positivity rates at the individual
level. To account for baseline differences that might bias the
estimate of impact on chlamydia positivity we included block
allocation, community risk level, and cluster size as covariates
and estimated the adjusted odds ratio.
The prevalence of chlamydia in the whole target population was
estimated by extrapolation from positivity rates among
participants by weighting based on demographic data available
for all invitees and an estimate of people being sexually active.
Therefore, cross tabulations of gender, age, ethnicity, and
community risk in participants and invited populations were
used to calculate survey weights for each invitation round
(demographic data for the whole target population were obtained
from the municipal register at the time of invitation). Weights
were calculated by dividing the proportion of participants with
a specified profile by the proportion of invitees with the same
profile (for example, the profile “<20 year old, Dutch, male”
represents 2% of the participant population but 4% of those
invited, so the weight assigned is 2). Firstly, the crude
prevalence in the invited population was estimated as the
weighted positivity rate. Estimates were then further adjusted
for sexual experience (assuming those who had never had sexual
intercourse to be uninfected) by multiplying these crude
prevalence rates by the fractions of sexually experienced women
and men by one year age bands using data from the National
Sexual Health Survey 2009.28 For South Limburg the estimates
were also adjusted for the exclusion of people with lower levels
of sexual risk behaviour by calculating a range of prevalence
estimates with maximum values based on the assumption that
the group excluded from participation because of a low score
in the risk assessment had the same positivity rate as the lowest
risk group included (with cut off score) and minimum values
assuming this group had zero positivity.
Estimated chlamydia prevalence was a pre-specified outcome,
but the results should be interpreted cautiously because probable
differences between participants and non-participants in sexual
risk level could not be taken into account (the information about
sexual behaviour was not available for non-participants and for
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55% of participants who did not fill in the online questionnaire
at baseline). We considered multiple imputation of data but
rejected it because the main parameters were systematically
missing for all non-participants and not scattered throughout
the dataset.
Secondary analyses compared changes in chlamydia positivity
in each region and in demographic subgroups (age, gender, and
ethnic group (based on participant’s country of birth and that
of his or her parents)). An indicator of socioeconomic status
based on income, education level, and employment was available
for the lowest level postcode areas (parts of streets) (Netherlands
Institute for Social Research). An additional, voluntary set of
questions about self reported pelvic inflammatory disease in
the preceding year was offered to female participants after they
had completed the general questionnaire (main question: “Have
you been diagnosed with a pelvic infection (an infection in the
ovaries or the uterus, not the bladder) in the past 12 months?”).
We used SPSS version 18 (IBM Corporation, Somers, New
York, USA) and SAS version 9.2 (SAS Institute, USA) for
statistical analyses.
Results
Population
From March 2008 to February 2011 a total of 834 971
invitations were sent to 421 820 individuals aged 16-29 years
in the three regions (table 1⇓). Of these, 162 096 received an
invitation in each of three consecutive years, showing the
mobility of the target population. Altogether, 102 283 samples
were returned by 79 173 people, and 4252 cases of chlamydia
infection were detected. At the time of analysis, 2661 of these
cases were retested after six months (uptake 65%). See the
figure⇓ for an overview of the study population in different
stages of the trial.
Participation
After the first invitation, 16.1% (43 358/269 273) of invitees in
blocks A and B returned a specimen; 10.8% (28 803/265 979)
returned one after the second invitation; and 9.5% (23 899/251
688) after the third invitation. The participation rate in the
control block C (invited after the second invitation in blocks A
and B) was 13.0% (6223/48 031). Similar trends in participation
rate per round were seen in each region (table 2⇓). Participation
in South Limburg was lower than in the cities because of the
use of the risk assessment. The downward trend in participation
over time was consistent across blocks when stratified by
community risk level and cluster size.
Women were more likely to take part than men in all three
invitation rounds (odds ratio, 2.34 (95% confidence interval
2.31 to 2.38)). Participation rates were higher among older age
groups (odds ratio 1.89 (1.85 to 1.92) for 25-29 year olds v
16-19 year olds), Dutch invitees versus invitees of non-Dutch
background (odds ratio 1.90 (1.87 to 1.92)), in people living in
clusters of low community risk (odds ratio 1.57 (1.54 to 1.61)
for low v high risk areas), and for people living in postcode
areas with high socioeconomic status scores (odds ratio 1.28
(1.24 to 1.33) for high v low socioeconomic status). These
differences were similar in consecutive screening rounds.
Percentage of positive chlamydia test results
(positivity)
The overall chlamydia positivity rate was 4.3% (1851/43 358)
among participants in the intervention blocks at the first
invitation, 4.0% (1153/28 803) at the second, and 4.1% (981/23
899) at the third invitation (table 3⇓). Chlamydia positivity in
the intervention blocks at the first invitation was the same as in
the control block (4.3%, table 1⇓) and 0.2% lower at the third
invitation than in the control block (odds ratio 0.96 (0.83 to
1.10)). The positivity rates in the control blocks in each region
were not all similar with those of the intervention blocks at the
start (table 3⇓). The difference between chlamydia positivity in
the intervention blocks at the third invitation and in the control
block was 0.05% in Amsterdam (3.4% v 3.4%, odds ratio 1.01
(0.81 to 1.26)), −0.27% in Rotterdam (5.3% v 5.5%, odds ratio
0.95 (0.77 to1.16)), and −1.02% in South Limburg (3.1% v
4.1%, odds ratio 0.74 (0.45 to 1.21)) (table 3⇓). In South
Limburg the difference reached the minimum level detectable
in power calculations, but statistical evidence for a difference
was weak because of low participation rates. There were some
differences in changes in positivity between blocks A and B but
these were not systematically related to community risk level
or cluster size. The odds for chlamydia positivity in the first
compared with the third invitation in all regions combined,
controlling for block allocation, community risk level, and
cluster size, was 0.97 (0.90 to 1.05), similar to the unadjusted
odds ratio.
Overall, women were more often chlamydia positive than men
(4.2% v 3.8%, odds ratio 1.12 (1.04 to 1.21)). Chlamydia
positivity rates were higher in young people under 20 years old
than among older invitees in all three rounds: at the first
invitation, 7.1% in <20 year olds, 4.9% in 20-24 year olds, and
2.7% in 25-29 year olds (odds ratio 2.70 (2.47 to 2.95)). There
were no marked differences in the change in positivity after two
or three invitations according to age. The positivity rate was
generally higher in clusters categorised as being at high risk
than low risk (6.7% v 3.0%, odds ratio 2.30 (2.10 to 2.52)), in
postcode areas with low socioeconomic status scores compared
with areas with high scores (4.6% v 2.4%, odds ratio 1.91 (1.54
to 2.37)) and among participants with non-Dutch background
compared with a Dutch background (5.6% v 3.4%, odds ratio
1.63 (1.53 to 1.74)). Declines in positivity were slightly greater
in high risk clusters than low risk clusters (−0.3% v 0.0%), in
low socioeconomic status postcodes than high status postcodes
(−0.8% v −0.1%), and in non-Dutch ethnic groups than Dutch
groups (−0.5% v −0.1%).
Repeated participation
People who had participated in a previous screening round were
more likely to participate again: 28-30% of initial participants
responded again when re-invited (round two n=10 474, round
three n=8298); 51% of people who participated twice did so
again at the third invitation (n=6001), but only 5% of those who
had not participated earlier did so on a following invitation.
Over three screening rounds, 25% of people who were invited
three times participated at least once (39 854), 8.3% participated
twice (13 441/162 096), and 2.8% participated three times
(4510/162 096). Among the people who participated in all three
rounds, the percentage with a positive chlamydia test fell from
5.9% in round one (264/4510) to 2.9% (131/4510) in round
three (difference −3.0%, odds ratio 0.49 (0.47 to 0.50)).
Incidence of self reported pelvic inflammatory
disease
The question on pelvic inflammatory disease was answered by
about 20% of female participants who completed the general
questionnaire (n=6420). Of these, 103 (1.6%) answered “Yes”
to having been diagnosed with a pelvic infection in the previous
year, while 300 women (4.8%) answered “I don’t know for
sure.” Among these “unsure” respondents there were 20 cases
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of potential pelvic inflammatory disease, comprising ovarian
infections diagnosed by ultrasound or other related medical
procedures or reporting symptoms consistent with infection.
The incidence of pelvic inflammatory disease among
respondents, including these possible cases, would be 1.9%.
The self reported incidence did not change over the three
invitations: 1.8% (19/1072) at the first invitation, 2.1%
(47/2261) at the second, and 1.9% (44/2340) at the third (odds
ratio 1.06 (0.62 to 1.83) comparing first with third invite).
Estimated population prevalence
The estimated population prevalence was lower than positivity
rates among the screening participants: 2.6% in Amsterdam,
3.7% in Rotterdam, and 3.2% in South Limburg in round one
(table 3⇓). The estimated prevalence in the third invitation round
was lower than in the control area in Amsterdam (2.5% v 3.0%)
and South Limburg (1.8% v 2.5%), but not in Rotterdam (both
3.9%). Prevalence estimates were generally higher in men than
in women; the decline in prevalence was strongest in women
aged >20 years.
Discussion
Main findings
In this controlled trial the participation rate was lower than
expected from an earlier pilot study and declined over the three
screening rounds. The chlamydia positivity rate in the
intervention blocks was 4.3% at baseline and 4.1% at the third
invitation, compared with 4.3% in the control block. There was
no statistical evidence of a reduction in chlamydia positivity in
the whole target population from systematic population based
screening, although results in South Limburg, where a risk based
selection was added, were more promising than in Amsterdam
and Rotterdam. Among the people taking part in all three years
(2.8% of all participants), chlamydia positivity declined from
6% at the first test to 3% at the third (difference −3.0%, odds
ratio 0.49 (0.47 to 0.50)).
Strengths and weaknesses of study
The main strengths of this trial were the evaluation of three
yearly rounds of chlamydia screening invitations in different
geographical settings in the Netherlands and the use of
population registers that showed who had and had not taken
part in screening. The stepped wedge design allowed
comparisons between screened and non-screened areas in a
logistically feasible way.
A limitation to the design of the trial was the non-random
allocation of clusters to intervention and control blocks. This
might have introduced selection bias if investigators deliberately
allocated specific clusters to block A, which was planned to
have the most screening rounds. We do not think this happened
because the investigators were blinded to the identity of clusters
and did not know whether the intervention effect might differ
by risk level or cluster size. The subsequent randomisation of
the order of implementation within blocks and addition of a
third round of screening in block B would also reduce the risk
of bias in the results.
The allocation achieved blocks of the required size, and the
magnitude of baseline imbalances according to level of
chlamydia risk could also have arisen by chance with random
allocation, which is acknowledged as a limitation of group level
interventions when the number of clusters is limited.29Although
we stratified the clusters according to community risk level, the
intervention and control block were not completely comparable
in all three regions. In addition, cluster allocation could have
reduced, but not eliminated, transmission of chlamydia within
clusters. Sexual networks do not strictly follow geographical
boundaries and the blocks for implementation were not
contiguous. Opportunities for chlamydia transmission between
clusters receiving screening invitations at different times would
dilute the effect of the intervention.
Of note, the participation rate in the control block C was not
completely comparable to that achieved after the first invitation
in the intervention blocks A and B, but was in between the
participation rates in rounds 1 and 2. Invitees in the control
group received their first invitation only in the second year of
the programme. It is conceivable that the initial uptake was
stimulated by the novelty and the boost of the publicity
generated at the start of the screening, the effect of which would
have waned by the time the control group got the invitation.
In practice, low uptake was probably the greatest barrier to
interrupting transmission. The low uptake also made it
impossible to estimate chlamydia prevalence reliably using
multiple imputation methods. Because of the lower than
expected participation, the estimates were extrapolated from a
small proportion of the target population. In addition, the
weights were based on demographics and proportion of people
who are sexually experienced but not other behavioural data.
The inverse probability weighting method assumed that
prevalence in the unscreened population was the same as in
participants with the same demographic profile. This is unlikely
because people accepting an offer to be screened for chlamydia
had higher levels of sexual risk behaviour and risk of chlamydia
infection than the general population, especially at the second
and third invitation.22 28 30 Therefore, we expect that the true
prevalence will be lower and the decline steeper.
Comparison with other studies
The results of this randomised trial give new information about
the effects of register based chlamydia screening over multiple
screening rounds on chlamydia prevalence at modest levels of
uptake. To our knowledge, these are the least biased estimates
available to date. Previous evidence came from ecological time
trend studies showing declines in rates of diagnosed chlamydia
or chlamydia positivity from countries conducting opportunistic
chlamydia screening from the late 1980s to mid 1990s.31-33 It is
difficult to know howmuch of the declines in these studies were
attributable to screening efforts because this time period
coincided with the early phase of the HIV epidemic, when there
were major publicity campaigns to encourage safer sexual
practices and reductions in sexual risk behaviour.11
Participation rates in this trial decreased after each round, which
was unexpected. However, this pattern has also been observed
for bowel cancer screening in the UK.34 The uptake of
opportunistic chlamydia screening in England has increased
over time with coverage of 33% in 2010-11.14 The studies that
examined the feasibility of one-off chlamydia screening
invitations showed higher uptake rates. The Dutch Ct-Pilot
Screening project achieved 30% participation in highly
urbanised areas.19 The Chlamydia Screening Studies (ClaSS)
project in England resulted in a 35% participation rate.17 18 In
those studies, the kits for home collection of specimens were
sent to the invitees (which is very costly to sustain), whereas in
our trial people had to log in to an internet website to request
the kit. In the United States, an internet based project offering
chlamydia screening has reported increasing numbers of
participants over time but does not actively offer regular
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screening, and numbers of test requests are low when related
to population size.35-37
Interpretation
The aim of the Chlamydia Screening Implementation
programme using home collected specimens was to supplement
the coverage of existing, clinic based, opportunistic chlamydia
testing to reduce the prevalence of chlamydia infection.
However, in spite of a personal invitation letter, easy online
home based procedures, and the use of text messaging and email
reminders to increase response rates, participation was too low
to reduce chlamydia transmission in the target population over
the three years of the intervention. The impact on self reported
pelvic inflammatory disease could not be assessed reliably. It
is still possible that register based chlamydia screening could
reduce chlamydia prevalence at the population level given more
time or in a different population, but we have observed that the
coverage and frequency of regular testing needed to achieve
this goal were not easy to reach.
There are several possible reasons for the lack of observed
effectiveness of chlamydia screening in this trial. First, the
intervention might not have been intensive enough to achieve
an effect. Second, any effect in the intervention blocks might
have been diluted by contamination from unscreened clusters
or areas outside the intervention regions. Third, the effective
difference in screening coverage between intervention and
control blocks was reduced by ongoing opportunistic testing
activity.
There are two lines of evidence suggesting that the intensity of
the intervention played a role. First, the percentage of positive
chlamydia tests fell markedly among people who were screened
in all three rounds. This effect was limited to only 3% of all
eligible participants, however. The low uptake of yearly
screening was in line with reports from Sweden, where, in a 10
year period, only 1.1% of women had 10 tests or more,38 and
the US, which found that in a five year period 0.1% of women
aged 15-25 years had a test every year.39 Second, in South
Limburg the positivity and prevalence estimates declined more
than in the cities. Here, a risk selection tool made screening
more efficient,27 but it did not reachmore people and the findings
in this rural area cannot be extrapolated to urban populations
directly.
People in both intervention and control blocks had access to
chlamydia testing; the average self reported testing rate for the
trial age group (16-29 years) in the Netherlands is estimated to
be 10-12% per year.28 The level of regular screening by people
tested opportunistically is not known. In the intervention blocks
the response rate, restricting the denominator to the sexually
active population, was 20% in the first year (25% in women
and 13% in men).22 40 Overall chlamydia test coverage in the
first year was therefore about 30% of sexually active 16-29 year
olds in the intervention blocks and 10% in the control block. It
is not known whether home based sampling replaced testing in
existing sexual health services, but visitor numbers at local
sexually transmitted infection clinics did not fall during the
study period.41 The positivity rates for chlamydia in sexually
transmitted infections clinics (12-13% for 16-29 year olds)41
and general practice (16% positive of tested42) are higher than
among those invited for screening, and people tested in sexually
transmitted infection clinics report higher numbers of partners
in the previous six months, more symptoms of infection, and
lower levels of condom use.41 The behavioural risk profile of
the participants in the Chlamydia Screening Implementation
programme was higher than that of adults of the same age in
the general population.22 On the other hand, non-responders
seemed to be at lower risk of infection and chose not to
participate for reasons such as not yet being sexually active,
self perceived low risk, or having had a recent test.22 Participants
who tested more than once tended to have higher risk sexual
behaviour.27 43 Self selection should have increased the yield of
prevalent infections detected.
Implications for research, practice and policy
The results of this study provide unique data that can be used
for future research.44 45 A dynamic network simulation model,
adapted from a previous model45 and using data from the
programme, suggests a proportional decrease of 20-30% in
positivity rates for chlamydia after 10 years if register based
screening was added to current opportunistic testing.46 Cost
effectiveness analysis indicates that this effect would be too
small to reach acceptable incremental cost effectiveness ratios
based on either major outcomes averted or quality adjusted life
years gained.47 For clinical practice, the high levels of repeat
infections after treatment (9% at six months48) suggest that
improvements in case management and partner notification
would benefit the infected individual.
The findings of the Chlamydia Screening Implementation
programme provide valuable practice based evidence showing
the limitations of the systematic screening approach in daily
reality. This contradicts the suggestion from a modelling study
that home based screening could have an impact on chlamydia
prevalence within a few years,49 but supports an earlier UK
expert opinion that register based chlamydia screening would
not be effective.50 There is, however, still no evidence of
effectiveness for the opportunistic approach chosen for the
English National Chlamydia Screening Programme either.11The
results of the Australian Chlamydia Control and Effectiveness
Pilot trial of multiple rounds of opportunistic chlamydia
screening in general practice could fill this evidence gap by
2014.51
There might be other settings where systematic screening would
work, for example in countries with higher prevalence or lower
levels of opportunistic testing. Evaluation of interventions in
cluster randomised trials with biological end points would be
valuable. The register based Chlamydia Screening
Implementation programme showed that yearly individual
invitations for three years and internet based home sampling
were logistically feasible but did not achieve sufficient or
sustained levels of uptake and did not reduce chlamydia
prevalence when compared with the control population. The
results of this trial do not support the national roll out of a
register based chlamydia screening programme.
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The results of this trial do not support the national roll out of this register based chlamydia screening programme
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Tables
Table 1| Baseline characteristics of clusters and individuals in the Chlamydia Screening Implementation programme, by block at enrolment
(see text for details)
TotalBlock CBlock BBlock A
% of
total
No of
individuals
(n=317 304)
No of
clusters
(n=190)
% of
total
per
block
No of
individuals
(n=48 031)
No of
clusters
(n=37)
% of
total
per
block
No of
individuals
(n=213 497)
No of
clusters
(n=114)
% of
total
per
block
No of
individuals
(n=55 776)
No of
clusters
(n=39)
Community risk:
18.558 6323423.611 331617.236 7322118.910 5697High
52.7167 1679149.223 6251853.0113 1415454.530 40119Medium
28.891 5056527.213 0751329.863 6243926.514 80613Low
Cluster size (quarters):
28.289 3999643.120 7022521.145 0784542.323 61926197-1596
24.477 4674127.713 324725.855 0632916.3908051597-2209
24.376 960319.34484228.260 2192422.012 25752210-2825
23.273 4782219.89521324.953 1371619.410 82032826-4538
Region:
50.0158 5458238.818 6261353.8114 8475645.025 07213Amsterdam
37.8119 8686234.416 5331040.285 7924231.517 54310Rotterdam
12.338 8914626.812 872146.012 8581623.613 16116South Limburg
Gender:
48.3153 346—49.723 884—48.0102 534—48.326 928—Male
51.7163 958—50.324 147—52.0110 963—51.728 848—Female
Age (years):
21.367 647—19.99574—21.445 667—22.212 406—16-19
36.8116 749—38.718 581—36.377 599—36.920 569—20-24
41.9132 908—41.419 876—42.390 231—40.922 801—25-29
Ethnic origin†:
50.2159 380—51.424 692—49.2105 018—53.229 670—Dutch
10.332 720—9.04315—11.324 195—7.54210—Surinamese/Antillean
16.050 687—16.27801—15.733 593—16.79293—Turkish/Moroccan
3.611 345—3.81814—3.77804—3.11727—Sub-Saharan African
19.963 172—19.69409—20.142 887—19.510 876—Other
Participation and chlamydia test positivity
15.613.016.315.5Participation (%)
4.284.304.274.31Chlamydia positivity
(%)
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Table 2| Participation in chlamydia screening, by region, sex, and screening invitation
Participation rate (% (95% CI))*No of people participatedNo of people invited
12.2 (11.7 to 12.8)102 283834 971Total:
16.1 (15.3 to 16.9)43 358269 2731st invitation
10.8 (10.3 to 11.4)28 803265 9792nd invitation
9.5 (9.0 to 10.0)23 899251 6883rd invitation
13.0 (11.4 to 14.7)622348 031Control
Region
Amsterdam:
17.2 (16.4 to 18.3)24 059139 9191st invitation
12.0 (11.2 to 12.8)16 355136 6892nd invitation
10.4 (9.6 to 11.3)13 866133 7363rd invitation
15.6 (12.5 to 19.3)289918 626Control
Rotterdam:
15.8 (14.6 to 17.1)16 414103 3351st invitation
10.2 (9.5 to 11.0)10 753104 6922nd invitation
8.7 (8.0 to 9.4)9057104 8853rd invitation
13.6 (11.8 to 15.6)225416 533Control
South Limburg:
11.1 (10.1 to 12.3)288526 0191st invitation
6.9 (6.2 to 7.6)168724 5982nd invitation
6.7 (5.8 to 7.6)87413 0673rd invitation
8.3 (7.1 to 9.8)107012 872Control
Gender
Male:
10.5 (10.0 to 11.0)13 617129 4621st invitation
6.7 (6.4 to 7.0)8616128 2992nd invitation
5.8 (5.5 to 6.0)6970121 1563rd invitation
8.5 (7.6 to 9.5)202523 884Control
Female:
21.3 (20.3 to 22.3)29 831142 4191st invitation
14.7 (13.9 to 15.4)20 246141 0782nd invitation
13.0 (12.2 to 13.8)16 853131 0103rd invitation
17.4 (15.1 to 19.9)419924 172Control
*Confidence intervals are corrected for cluster effect (inter-cluster effect on participation was significant).
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Table 3| Chlamydia test positivity and estimated population prevalence, by region, sex and screening invitation
Estimated
prevalence (%
(95% CI))*
Change in positivity compared with control blockChange in
positivity
from 1st
invite (%)
No (%) positive for
chlamydia
No of people
who participated Odd ratio (95% CI); P valueChange (%)
2.74252 (4.2)102 283Total:
2.61.00 (0.87 to 1.13); 0.94−0.02—1851 (4.3)43 3581st invitation
2.60.93 (0.81 to 1.07); 0.30−0.29−0.31153 (4.0)28 8032nd invitation
2.60.96 (0.83 to 1.10); 0.52−0.19−0.2981 (4.1)23 8993rd invitation
3.01.00 (reference)——267 (4.3)6223Control
Region
Amsterdam:
2.6 (2.4 to 2.8)1.07 (0.87 to 1.33); 0.510.24—871 (3.6)24 0591st invitation
2.5 (2.3 to 2.7)1.02 (0.82 to 1.27); 0.840.07−0.2565 (3.5)16 3552nd invitation
2.5 (2.2 to 2.7)1.01 (0.81 to 1.26); 0.920.05−0.2476 (3.4)13 8663rd invitation
3.0 (2.1 to 3.9)1.00 (reference)——98 (3.4)2899Control
Rotterdam:
3.7 (3.4 to 3.9)1.06 (0.95 to 1.19); 0.30−0.46—834 (5.1)16 4141st invitation
3.5 (3.2 to 3.8)0.91 (0.75 to 1.11); 0.36−0.72−0.3519 (4.8)10 7532nd invitation
3.9 (3.6 to 4.3)0.95 (0.77 to 1.16); 0.60−0.270.2478 (5.3)90573rd invitation
3.9 (3.2 to 4.6)1.00 (reference)——125 (5.5)2254Control
South Limburg:
3.2 (2.7–3.6)†1.24 (0.88 to 1.75); 0.220.95—146 (5.1)28851st invitation
2.6 (2.4–2.8)†0.99 (0.67 to 1.46); 0.96−0.02−1.069 (4.1)16872nd invitation
1.8 (1.7–1.9)†0.74 (0.45 to 1.21); 0.23−1.02−2.027 (3.1)8743rd invitation
2.5 (2.3–2.6)†1.00 (reference)——44 (4.1)1070Control
Gender
Male:
3.50.94 (0.74 to 1.20); 0.64−0.22—522 (3.8)13 6171st invitation
3.30.91 (0.71 to 1.16); 0.45−0.36−0.1318 (3.7)86162nd invitation
3.61.00 (0.78 to 1.29); 0.980.010.2283 (4.1)69703rd invitation
3.81.00 (reference)——82 (4.0)2025Control
Female:
3.11.02 (0.87 to 1.19); 0.850.05—1329 (4.5)29 8311st invitation
2.70.94 (0.80 to 1.10); 0.43−0.28−0.3835 (4.1)20 2462nd invitation
2.90.93 (0.79 to 1.10); 0.42−0.26−0.3698 (4.1)16 8533rd invitation
3.11.00 (reference)——185 (4.4)4199Control
*Confidence intervals are not corrected for cluster effect (inter-cluster effect on positivity was not significant). Confidence intervals could not be calculated for South
Limburg, so they are also unavailable for the total population and estimates by gender.
†Values are intermediates with high and low estimates rather than confidence intervals.
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Figure
Fig Flow chart of the Chlamydia Screening Implementation programme
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